checkAd

     169  0 Kommentare Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) - Seite 3

    • Identification and Characterization of STAC-BBB, an Engineered AAV Capsid That Exhibits Widespread Transduction of the Central Nervous System in Cynomolgus Macaques
      • Abstract No. 117
      • Oral Presentation – May 8; 4:00-4:15 pm ET
    • A Highly Potent Engineered AAV Capsid, STAC-150, Enables High-Throughput AAV Production and Arrayed Epigenetic Regulator Screening Directly in Cultured Neurons
      • Abstract No. 351
      • Oral Presentation – May 10; 5:15-5:30 pm ET
    • Optimal Drug Product Presentation and Container Closure Selection for AAV-Based Genomic Medicines
      • Abstract No. 547
      • Poster Presentation – May 8; 5:30-7:00 pm ET
    • Development of Blood-Brain Barrier Penetrant AAVs through Receptor-Targeted Capsid Engineering
      • Abstract No. 985
      • Poster Presentation – May 9; 5:30-7:00 pm ET
    • Unraveling Impact of Manufacturing Process-Related Stresses on AAV Stability, Aggregation, and DNA Release
      • Abstract No. 1032
      • Poster Presentation – May 9; 5:30-7:00 pm ET
    • Process and Formulation Development for a Novel Blood-Brain Barrier Penetrant AAV Capsid
      • Abstract No. 1052
      • Poster Presentation – May 9; 5:30-7:00 pm ET

    Next-Generation Genome Engineering

    • Directed Evolution of Bxb1 for the Development of Modular Integrases (MInts)
      • Abstract No. 192
      • Oral Presentation – May 9; 4:00-4:15 pm ET
    • Zinc Finger Mediated Repression and Replacement of MFN2 Leads to the Rescue of Cellular Disease Phenotype in CMT2A Patient-Derived Cells
      • Abstract No. 637
      • Poster Presentation – May 8; 5:30-7:00 pm ET
    • Highly Specific Zinc Finger Proteins with Synthetic Target Sites Enable Self-Regulated Expression of Dosage-Sensitive Transgenes
      • Abstract No. 722
      • Poster Presentation – May 8; 5:30-7:00 pm ET
    • Site-directed integration of large DNA sequences into endogenous sites in the human genome using engineered Modular Integrases (MInts)
      • Abstract No. 1680
      • Poster Presentation – May 10; 5:30-7:00 pm ET

    All abstracts for the ASGCT Annual Meeting are available on ASGCT’s website.

    Seite 3 von 5



    Diskutieren Sie über die enthaltenen Werte



    Business Wire (engl.)
    0 Follower
    Autor folgen

    Weitere Artikel des Autors


    Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) - Seite 3 Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 20 Sangamo abstracts for presentation at the 27th ASGCT Annual Meeting being held May 7-11, …